WallStSmart

InnovAge Holding Corp (INNV)vsNovartis AG ADR (NVS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Novartis AG ADR generates 5628% more annual revenue ($56.69B vs $989.71M). NVS leads profitability with a 22.5% profit margin vs -0.3%. NVS earns a higher WallStSmart Score of 51/100 (C-).

INNV

Avoid

26

out of 100

Grade: F

Growth: 6.0Profit: 3.5Value: 4.0Quality: 6.5
Piotroski: 4/9Altman Z: 2.48

NVS

Buy

51

out of 100

Grade: C-

Growth: 4.0Profit: 9.0Value: 3.3Quality: 4.5
Piotroski: 4/9Altman Z: 1.96
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

INNVSignificantly Overvalued (-19.4%)

Margin of Safety

-19.4%

Fair Value

$6.85

Current Price

$10.92

$4.07 premium

UndervaluedFair: $6.85Overvalued
NVSSignificantly Overvalued (-47.0%)

Margin of Safety

-47.0%

Fair Value

$93.29

Current Price

$140.37

$47.08 premium

UndervaluedFair: $93.29Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

INNV1 strengths · Avg: 8.0/10
Revenue GrowthGrowth
18.3%8/10

18.3% revenue growth

NVS5 strengths · Avg: 9.4/10
Market CapQuality
$260.70B10/10

Mega-cap, among the largest globally

Return on EquityProfitability
30.7%10/10

Every $100 of equity generates 31 in profit

Operating MarginProfitability
34.6%10/10

Strong operational efficiency at 34.6%

Profit MarginProfitability
22.5%9/10

Keeps 23 of every $100 in revenue as profit

Free Cash FlowQuality
$5.57B8/10

Generating 5.6B in free cash flow

Areas to Watch

INNV4 concerns · Avg: 2.0/10
Market CapQuality
$1.49B3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-9.7%2/10

ROE of -9.7% — below average capital efficiency

EPS GrowthGrowth
-87.8%2/10

Earnings declined 87.8%

Profit MarginProfitability
-0.3%1/10

Currently unprofitable

NVS4 concerns · Avg: 3.3/10
Revenue GrowthGrowth
0.8%4/10

0.8% revenue growth

Altman Z-ScoreHealth
1.964/10

Grey zone — moderate risk

Debt/EquityHealth
1.183/10

Elevated debt levels

PEG RatioValuation
3.222/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : INNV

The strongest argument for INNV centers on Revenue Growth. Revenue growth of 18.3% demonstrates continued momentum.

Bull Case : NVS

The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 22.5% and operating margin at 34.6%.

Bear Case : INNV

The primary concerns for INNV are Market Cap, Return on Equity, EPS Growth.

Bear Case : NVS

The primary concerns for NVS are Revenue Growth, Altman Z-Score, Debt/Equity.

Key Dynamics to Monitor

INNV profiles as a growth stock while NVS is a value play — different risk/reward profiles.

NVS carries more volatility with a beta of 0.49 — expect wider price swings.

INNV is growing revenue faster at 18.3% — sustainability is the question.

NVS generates stronger free cash flow (5.6B), providing more financial flexibility.

Bottom Line

NVS scores higher overall (51/100 vs 26/100), backed by strong 22.5% margins. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

InnovAge Holding Corp

HEALTHCARE · MEDICAL CARE FACILITIES · USA

InnovAge Holding Corp. The company is headquartered in Denver, Colorado.

Visit Website →

Novartis AG ADR

HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA

Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.

Visit Website →

Want to dig deeper into these stocks?